ArticleLangenbeck's archives of surgery2022
Incidence and risk factor for infection of totally implantable venous access port.
Article in Langenbeck's archives of surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Transverse versus longitudinal skin incisions for totally implantable venous access port implantation: a randomized controlled trial.Langenbeck's archives of surgery · 2026Trial
- Use of plastic adhesive skin drapes in cancer patients undergoing totally implantable vascular access port (TIVAP) placement-a randomized controlled pilot study.Langenbeck's archives of surgery · 2022Trial
- Addressing infection in totally implantable venous access ports: An ex vivo study on bacterial transfer and the Forsvall Port needle design.The journal of vascular access · 2026Article
- Effects of totally implantable venous access ports on complications and quality of life in gastrointestinal cancer chemotherapy.World journal of gastrointestinal surgery · 2025Article
- Prospective, monocentric observational study on the clinical use and patient satisfaction of an implantable venous access Port.Langenbeck's archives of surgery · 2025Observational
- Machine learning risk prediction model for bloodstream infections related to totally implantable venous access ports in patients with cancer.Asia-Pacific journal of oncology nursing · 2024Article
- Development and Validation of an Electronic Adverse Event Model for Patient Safety Surveillance in Interventional Radiology.Journal of the American College of Radiology : JACR · 2024Article
- Is ultrasound guidance necessary to avoid complications in the implantation of venous access ports?Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2024Article
- Totally implantable venous ports in infants and children: a single-center retrospective study of indications and safety.Frontiers in oncology · 2024Article
- Factors associated with morbidity of a totally implantable venous access device in patients with breast cancer.Turkish journal of medical sciences · 2024Article
- Predictors of central line-associated bloodstream infections in cancer patients undergoing chemotherapy through implanted venous access ports: a retrospective, observational study.Translational cancer research · 2023Article
- Silver-Mixed Port Reduces Venous Access Port Related Infection Rate Compared to Non-Silver-mixed Port: A Single-center Retrospective Analysis.Cardiovascular and interventional radiology · 2023Article
- Port catheter tip positioning is essential.Langenbeck's archives of surgery · 2022Article
- Reply to Dr. Toro's letter to editor "Port catheter tip positioning is essential".Langenbeck's archives of surgery · 2022Article
- Risk Factors of Catheter-Related Infection in Unplanned Extubation of Totally Implantable Venous-Accessportsin Tumor Patients.Emergency medicine international · 2022Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTotally implantable venous access ports (TIVAP) have been widely used in cancer patients for many years. The early infection (within 30 days after TIVAP implantation) rate of TIVAP accounts for about one-third of all TIVAP infections, and early infection often causes port removal and affects subsequent cancer treatment. This study investigated the incidence and risk factors for early and late infection after TIVAP implantation.
methodsFrom January 2013 to December 2018, all adult cancer patients who received TIVAP implantation in Taipei Medical University Shuang-Ho Hospital were reviewed. We evaluated the incidence of TIVAP-related infection, patient characteristics, and bacteriologic data. Univariable analysis and multiple logistic regression analysis were used to evaluate the risk factors of TIVAP-related infection.
resultsA total of 3001 TIVAPs were implanted in 2897 patients, and the median follow-up time was 424 days (range: 1-2492 days), achieving a combined total of 1,648,731 catheter days. Thirty-one patients (1.0%) had early infection and 167 (5.6%) patients had late infection. In multivariate analysis, TIVAP combined with other surgeries (p = 0.03) and inpatient setting (p < 0.001) was the risk factor of early infection, and TIVAP combined with other surgeries (p = 0.007), hematological cancer (p = 0.03), and inpatient setting (p < 0.001) was the risk factor of late infection.
conclusionInpatient TIVAP implantation and TIVAP implantation combined with other surgeries are associated with high rates of TIVAP-related early and late infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.